United States Insulin Market Assessment, By Product [Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar, Others], By Type [Human Insulin, Insulin Analog], By Application [Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies], By Region, Opportunities and Forecast, 2018-2032F
Market Report I 2025-06-16 I 159 Pages I Market Xcel - Markets and Data
United States insulin market is projected to witness a CAGR of 2.89% during the forecast period 2025-2032, growing from USD 8.10 billion in 2024 to USD 10.17 billion in 2032. The market's growth and expansion are supported by the rising cases of diabetes, increasing investments in research and development activities, and the strong presence of leading pharmaceutical companies in the country. As per the estimates of the Centers for Disease Control and Prevention, approximately 38 million people in the United States have diabetes. The rapid expansion of the geriatric population, increasing awareness about diabetes, and growing incidences of obesity are further augmenting the market's demand.
Obesity increases the risk of developing type 2 diabetes as excessive body weight adds to insulin resistance, making it difficult to regulate blood glucose levels. The Centers for Disease Control and Prevention estimates that more than 2 in 5 adults in the United States have obesity. As obesity rates continue to increase, the requirement for effective diabetes management solutions is expected to rise in the United States, providing lucrative growth opportunities for the market.
Rising Collaborations Support Market Expansion
Strategic partnerships between pharmaceutical and biotechnology companies and healthcare organizations are allowing the pooling of resources, expertise, and manufacturing capabilities, which in turn are accelerating the development and distribution of insulin therapies across the country. Furthermore, collaborations also support the introduction of innovative insulin formulations and delivery systems, allowing pharmaceutical companies to meet the diverse requirements of the patient population and expand their presence in the industry. For instance, in February 2025, Oramed Pharmaceuticals Inc. announced a joint venture with Hefei Tianhui Biotech Co., Ltd. to form OraTech Pharmaceuticals Inc. to accelerate the development and delivery of Oramed's oral insulin (ORMD-0801) and other Protein Oral Delivery (POD) technologies. With an emphasis on commercialization and development, a pipeline poised for clinical advancements, and a strong financial foothold, OraTech is expected to transform oral biologics and redefine diabetes care.
Supportive Government Policies Boost Market Growth
The introduction of supportive government policies is playing a crucial role in shaping the trajectory of the market in the United States. In response to public pressure and advocacy, several state governments and federal programs have introduced price caps on insulin. The Inflation Reduction Act of 2022, for instance, implemented a USD 35 monthly cap on insulin for Medicare beneficiaries. This has positively impacted prescription adherence and reduced emergency hospital visits due to unmanaged diabetes. For instance, in March 2023, Eli Lilly announced a 70% reduction in the list prices of its most commonly prescribed insulins and expanded its Insulin Value Program, capping out-of-pocket costs at USD 35 or less per month.
Furthermore, legislative support is also bolstering investments in domestic insulin production, including initiatives to support nonprofit insulin manufacturers.
Technological Advancements Drive Market Demand
The integration of digital tools with insulin therapy is transforming diabetes management and allowing the patient population to live a normal life. Smart insulin pens, continuous glucose monitors, and insulin pumps are enabling patients to better monitor and control their blood sugar levels. These advanced devices are connected to smartphone apps, offering real-time data sharing and decision support systems that enhance adherence and patient outcomes. Leading medical device providers are also working on launching new technologies and products to ensure patient compliance by enhancing their comfort. For instance, in April 2023, Medtronic plc received approval from the US Food and Drug Administration (FDA) for its MiniMed 780G system with the Guardian 4 sensor, marking the approval of the first system to provide meal detection technology. Such launches are allowing patients to monitor their blood glucose levels with ease and improving patient outcomes.
Online Pharmacies Expected to Witness Significant Growth
The segment's growth is supported by the evolving consumer preferences and competitive pricing and convenience offered by online pharmacies. The rising availability of telehealth services across the United States, coupled with the expansion of e-commerce platforms, further supports online pharmacies' growth. These platforms often provide lucrative discounts, home delivery, and automated prescription refills, allowing patients to manage chronic conditions such as diabetes with ease. Additionally, leading online pharmacies are focusing on enhancing the quality of the services that they provide, allowing them to hold a major share of the market. For instance, in October 2024, Amazon.com, Inc. announced plans to expand their same-day prescription delivery services to twenty more cities in the United States by the end of 2025.
Impact of the U.S. Tariffs on the United States Insulin Market
- Insulin prices in the United States are expected to increase significantly following the introduction of tariffs as the manufacturers might pass the additional expenses onto the consumers, posing significant challenges for underinsured or uninsured consumers who already face high out-of-pocket costs for insulin.
- The tariffs are also expected to disrupt supply chains, resulting in potential insulin availability delays, forcing manufacturers to restore their production and seek alternative sources for active pharmaceutical ingredients.
- The estimated escalation in costs could potentially strain insurance and healthcare providers, resulting in reduced coverage and higher premiums for the patient population.
Key Players Landscape and Outlook
The key players in the market are focusing on partnerships and collaborations to bolster the accessibility of insulin across the United States. For instance, in March 2025, Biocon Biologics Limited, a subsidiary of Biocon Limited, partnered with Civica, Inc. to increase the affordability and accessibility of Insulin Aspart in the country. Under the agreement terms, Biocon Biologics will provide Insulin Aspart substance to Civica, which will manufacture the rapid-acting insulin analog in Virginia, United States. The latter will also commercialize the medicine in the country. Such partnerships showcase the commitment of the leading market players in ensuring the supply of life-saving medications and are expected to provide lucrative growth opportunities for the market.
1. Project Scope and Definitions
2. Research Methodology
3. Impact of U.S. Tariffs
4. Executive Summary
5. United States Insulin Market Outlook, 2018-2032F
5.1. Market Size Analysis & Forecast
5.1.1. By Value
5.2. Market Share Analysis & Forecast
5.2.1. By Product
5.2.1.1. Rapid-Acting Insulin
5.2.1.2. Long-Acting Insulin
5.2.1.3. Combination Insulin
5.2.1.4. Biosimilar
5.2.1.5. Others
5.2.2. By Type
5.2.2.1. Human Insulin
5.2.2.2. Insulin Analog
5.2.3. By Application
5.2.3.1. Type 1 Diabetes Mellitus
5.2.3.2. Type 2 Diabetes Mellitus
5.2.4. By Distribution Channel
5.2.4.1. Hospital Pharmacies
5.2.4.2. Retail Pharmacies
5.2.4.3. Online Pharmacies
5.2.5. By Region
5.2.5.1. Northeast
5.2.5.2. Midwest
5.2.5.3. West
5.2.5.4. South
5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
5.3. Market Map Analysis, 2024
5.3.1. By Product
5.3.2. By Type
5.3.3. By Application
5.3.4. By Distribution Channel
5.3.5. By Region
6. Demand Supply Analysis
7. Value Chain Analysis
8. Porter's Five Forces Analysis
9. PESTLE Analysis
10. Pricing Analysis
11. Market Dynamics
11.1. Market Drivers
11.2. Market Challenges
12. Market Trends and Developments
13. Regulatory Framework and Innovation
13.1. Clinical Trials
13.2. Regulatory Approvals
14. Patent Landscape
15. Case Studies
16. Competitive Landscape
16.1. Competition Matrix of Top 5 Market Leaders
16.2. SWOT Analysis for Top 5 Players
16.3. Key Players Landscape for Top 10 Market Players
16.3.1. Novo Nordisk Inc.
16.3.1.1. Company Details
16.3.1.2. Key Management Personnel
16.3.1.3. Products and Services
16.3.1.4. Financials (As Reported)
16.3.1.5. Key Market Focus and Geographical Presence
16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
16.3.2. Sanofi S.A.
16.3.3. F. Hoffmann-La Roche AG
16.3.4. Wockhardt Limited
16.3.5. Eli Lilly USA, LLC
16.3.6. Biocon Limited
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
17. Strategic Recommendations
18. About Us and Disclaimer
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.